Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer, U Blanc, J Melisi, D Cubillo, A Von Hoff, D Wang-Gillam, A Chen, L Siveke, J Wan, Y Solem, C
Pelzer, U
Blanc, J
Melisi, D
Cubillo, A
Von Hoff, D
Wang-Gillam, A
Chen, L
Siveke, J
Wan, Y
Solem, C
Citations
Altmetric:
Abstract
In the NAPOLI-1 Phase 3 trial, nal-IRI+5-fluorouracil and leucovorin (5-FU/LV) significantly improved median overall survival (6.1 vs 4.2 months, P=0.012) and progression-free survival (3.1 vs 1.5 months, P=0.0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy. This analysis evaluated between treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST).
Description
Date
2017-03-28
Publisher
Collections
Keywords
Type
Article
Citation
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. 2017, Br J Cancer